Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19308814 | 0.89 | EGFR (0.38) | EGFRPIK3CAPIK3CDFGFR4AR | |
| SCHEMBL2619213 | 0.75 | EGFR (0.50) | EGFRPIK3CAPIK3CDFGFR4AR | |
| SCHEMBL1771615 | 0.72 | EGFR (0.60) | EGFRIMPDH2CYP1A2 | |
| SCHEMBL29985188 | 0.72 | EGFR (0.60) | EGFRIMPDH2PIK3CAPIK3CDFGFR4 | |
| SCHEMBL1771905 | 0.72 | EGFR (0.60) | EGFRIMPDH2PIK3CAPIK3CDFGFR4 | |
| SCHEMBL19308857 | 0.71 | EGFR (0.38) | EGFRIMPDH2PIK3CAPIK3CD | |
| SCHEMBL2611054 | 0.70 | EGFR (0.55) | EGFRPIK3CAPIK3CDFGFR4AR | |
| SCHEMBL28801910 | 0.70 | EGFR (0.58) | EGFRIMPDH2PIK3CAPIK3CDFGFR4 | |
| SCHEMBL23335615 | 0.68 | EGFR (0.51) | EGFRIMPDH2PIK3CAPIK3CDFGFR4 | |
| SCHEMBL27666530 | 0.68 | EGFR (0.51) | EGFRPIK3CAPIK3CDFGFR4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085386-A1 | URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085386-A1 | URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | EGFR 4021/4885IMPDH2 400/4885PIK3CA 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.